Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04907201
Other study ID # H20-02294
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date December 15, 2020
Est. completion date November 2024

Study information

Verified date June 2024
Source Vancouver Island Health Authority
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Spasticity is a common complication after many upper motor neurone disorders. Many surgical techniques have been introduced for patients with refractory spasticity though they are not without peri-operative risks. Cryoneurotomy is another procedure which is cheaper, faster and less invasive in comparison to other surgical interventions. While many studies support the use of cryoneurotomy for pain relief, there are not much studies on use of cryoneurotomy to manage spasticity. The purpose of this study to measure the effect of tibial nerve cryoneurotomy on electrophysiological and clinical spasticity measures in adult patients with spastic equinovarus or equinus foot, who will receive this procedure as a part of their treatment based on spasticity treatment available guidelines. The results will provide us valuable information like how long cryoneurotomy is effective, before regeneration happens.


Description:

Different surgical techniques, including muscle and tendon lengthening and neurotomy/neurectomy (surgical sectioning of a peripheral nerve) are reserved for patients with refractory spasticity. Cryoneurotomy which involves direct application of a low temperature probe to a nerve is another procedure, which is cheaper, faster and less invasive than surgical intervention, for the treatment of refractory spasticity. While many studies support using of cold temperature in pain relief (Ilfeld BM, 2017, Friedman, T. 2012), there are not much studies on use of cryoneurotomy to manage spasticity.This clinic has been using cryoneurotomy clinically with empiric success for 2.5 years. The initial results reveal significant increased active and passive range of motion in upper limbs and decreased clonus and improved gait after tibial neurotomy in lower limbs. Spastic equinovarus foot (SEF) which is a common type of lower limb spasticity is typically treated with focal botulinum toxin injections, bracing and therapeutic exercise, although the drawback of these treatments is the need for serial injections and frequent interactions with health care providers. Recently selective tibial neurotomy has been shown to more definitively treat SEF (Bollens B, et al.2011, Deltombe T, et al. 2015), but as mentioned above this is an invasive approach. In light of our promising clinical experience with cryoneurotomy, we propose to prospectively and systematically measure its effect on SEF, as an alternative to more invasive surgical procedures and the typical multi-modal approach. The data collection fro this project which is a single-centre, prospective cohort study will occur at the Victoria General Hospital (VGH) multidisciplinary spasticity clinic. Patients with spasticity are referred to this clinic for different procedures including cryoneurotomy. This study will not interfere or change the patients' medical care, and the assessments will be done for the patients who are already candidates for this procedure as a part of their treatment, besides other provided medical cares and have been accepted to receive that.These participants will be invited to have an extra electrophysiological test for being enrolled in this study, which will be performed before the procedure and at 1, 3 and 12 months after cryoneurotomy. In addition, the results of their routine physical examinations including spasticity degree and ankle passive range of motion will be collected in this study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date November 2024
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria for patient group: 1. Patients who will have cryoneurotomy as part of their standard treatment for spastic equinovarus foot in VGH spasticity multidisciplinary clinic 2. Adults 18-70 years of age (male and female) 3. Ability to attend testing sessions, comply with testing protocols and provide written informed consent. 4. Able to understand and complete study-related questionnaires (must be able to understand and speak English or have access to an appropriate interpreter as judged by the investigator). Inclusion Criteria for healthy participants: 1. Any healthy participants with the age between 18 to 70. Over 70 will be excluded due to the expected natural alterations in electrophysiological parameters 2. Able to attend and comply with the testing protocols 3. Able to provide informed written consent 4. Able to understand and speak English or have access to an appropriate interpreter Exclusion Criteria: 1. History of previous nerve procedures such as chemical neurolysis with alcohol, cryoneurotomy, any surgery of the tibial nerve. 2. Any other neurological pathology different from that responsible for the spasticity.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Cryoneurotomy
Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.

Locations

Country Name City State
Canada Victoria General Hospital Victoria British Columbia

Sponsors (1)

Lead Sponsor Collaborator
Vancouver Island Health Authority

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Bollens B, Deltombe T, Detrembleur C, Gustin T, Stoquart G, Lejeune TM. Effects of selective tibial nerve neurotomy as a treatment for adults presenting with spastic equinovarus foot: a systematic review. J Rehabil Med. 2011 Mar;43(4):277-82. doi: 10.2340/16501977-0786. — View Citation

Deltombe T, Bleyenheuft C, Gustin T. Comparison between tibial nerve block with anaesthetics and neurotomy in hemiplegic adults with spastic equinovarus foot. Ann Phys Rehabil Med. 2015 Apr;58(2):54-9. doi: 10.1016/j.rehab.2014.12.003. Epub 2015 Jan 9. — View Citation

Friedman T, Richman D, Adler R. Sonographically guided cryoneurolysis: preliminary experience and clinical outcomes. J Ultrasound Med. 2012 Dec;31(12):2025-34. doi: 10.7863/jum.2012.31.12.2025. — View Citation

Ilfeld BM, Gabriel RA, Trescot AM. Ultrasound-guided percutaneous cryoneurolysis for treatment of acute pain: could cryoanalgesia replace continuous peripheral nerve blocks? Br J Anaesth. 2017 Oct 1;119(4):703-706. doi: 10.1093/bja/aex142. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Any changes in H max to M max amplitude ratio (H/ M ratio) The ratio of maximum H reflex amplitude to maximum M wave amplitude as another electrophysiological analog for spasticity will be measured by a commercially available clinical electrodiagnosis machine before the procedure and at 1, 3 and 12 months after it. The results will be presented as a ratio and percentage. up to 12 months
Primary Changes in maximum H reflex amplitude The maximum H reflex amplitude as an analog of spasticity as it measure excitability of the monosynaptic reflex arc will be assessed by a commercially available clinical electrodiagnosis machine. The assessment will be done before the procedure and at 1, 3 and 12 months after it and at both sides. The measurement unit will be millivolt (mV). up to 12 months after procedure
Secondary Degree of changes in ankle dorsi-flexion spasticity as measured by Modified Ashworth Scale (MAS) MAS has 6 scales from 0 to 4 (0,1,1+,2,3,4) which 0 means no spasticity and 4 means the maximum spasticity and the affected limb is rigid in its position.The assessment will be done by a trained examiner which is not enrolled in providing medical care and will be done before the procedure and at 1, 3 and 12 months after the procedure. up to 12 months after procedure
Secondary Degree of changes in ankle dorsiflexion range of motion The active and maximum passive dorsiflexion range of motion will be measured by a goniometer and will be presented in degree. The test will be done before and at 1, 3 and 12 months after the procedure by a trained examiner who is not enrolled in providing medical care. Up to 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT02907775 - Multi-channel Stimulation for Post Stroke Spasticity (MUSTS) N/A
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Active, not recruiting NCT03521076 - Randomized Controlled Trial of Virtual Reality N/A
Completed NCT03080454 - The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke Phase 1/Phase 2
Completed NCT02546999 - Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Phase 4
Active, not recruiting NCT01041157 - Botulinum Toxin Injection Efficiency Phase 1
Terminated NCT00532532 - Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis Phase 2
Terminated NCT00531466 - Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury Phase 2
Completed NCT00535938 - MDs on Botox Utility (MOBILITY) N/A
Completed NCT05546190 - A Study to Collect Participants Experience of Living With Adult Upper Limb (AUL) Spasticity and to Assess the Arm Activity Measure (ArmA)
Recruiting NCT06117020 - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals Phase 1
Completed NCT01603628 - BOTOX® Treatment in Pediatric Lower Limb Spasticity Phase 3
Completed NCT05510726 - Quantitative Evaluation of Muscle Stiffness in Neurological Patients With Muscle Overactivity
Not yet recruiting NCT04378946 - Error Augmentation Motor Learning Training Approach in Stroke Patients N/A
Completed NCT01603615 - BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity Phase 3
Completed NCT01251380 - Dysport® Pediatric Lower Limb Spasticity Follow-on Study Phase 3
Completed NCT00549783 - BOTOX® Economic Spasticity Trial (BEST) Phase 4
Completed NCT00210431 - Post Marketing Surveillance Study of Dysport
Completed NCT00076687 - Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function Phase 2